Cargando…
Does Menopausal Status Affect Dry Eye Disease Treatment Outcomes with OC-01 (Varenicline Solution) Nasal Spray? A Post Hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials
INTRODUCTION: This study sought to compare the efficacy of OC-01 (varenicline solution) nasal spray for treatment of dry eye disease (DED) in postmenopausal women (PM+) versus women who were not postmenopausal (PM−). METHODS: This was a post hoc subgroup analysis of data integrated from two prior ra...
Autores principales: | Nijm, Lisa M., Zhu, Dagny, Hemphill, Mandy, Blemker, Gretchen L., Hendrix, Laura H., Kabat, Alan G., Gibson, Andrea A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834459/ https://www.ncbi.nlm.nih.gov/pubmed/36401081 http://dx.doi.org/10.1007/s40123-022-00607-7 |
Ejemplares similares
-
OC-01 (Varenicline Solution) Nasal Spray Demonstrates Consistency of Effect Regardless of Age, Race, Ethnicity, and Artificial Tear Use
por: Epitropoulos, Alice T, et al.
Publicado: (2022) -
OC-01 (Varenicline Solution) Nasal Spray for the Treatment of Dry Eye Disease Signs and Symptoms in Subjects with Autoimmune Disease: Integrated Data from ONSET-1 and ONSET-2
por: Schallhorn, Julie M, et al.
Publicado: (2023) -
Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease
por: Hauswirth, Scott G, et al.
Publicado: (2023) -
Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?
por: Sheppard, John D., et al.
Publicado: (2023) -
Semi-PBPK Modeling and Simulation to Evaluate the Local and Systemic Pharmacokinetics of OC-01(Varenicline) Nasal Spray
por: Wu, Xiaofei, et al.
Publicado: (2022)